Trastuzumab Emtansine (T-DM1) increases progression-free survival (PFS) in metastatic breast cancer patients compared to patients who received lapatinib (Tykerb;
GlaxoSmithKline Plc) and
capecitabine (Xeloda; Roche) combination, Roche made the announcement today in a press release. The overall surivival (OS) data is not mature yet.
Oncology targets, strategies, cancer drug development and personalized medicine
Showing posts with label lapatinib. Show all posts
Showing posts with label lapatinib. Show all posts
Saturday, March 31, 2012
Thursday, January 19, 2012
One-Two Punch: Curbing HER-2 Positive Breast Cancer with Herceptin-Tykerb Combo
Using Tykerb (lapatinib; GlaxoSmithKline, U.K.) and Herceptin (trastuzumab; Genentech, South San Francisco, Calif.) anti-HER-2 drugs together doubles the odds of recovery compared to either drug alone in HER-2 positive early breast cancer patients, reports NeoALTTO trial investigators in the January 17th online publication at Lancet Oncology journal homepage. This study provides a proof-of-concept that dual HER-2 block is better than using a single agent HER-2 blocker.
Subscribe to:
Posts (Atom)